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OBJECTIVES The goal of this study was to assess the presence of systemic inflammation in degenerative
aortic valvular stenosis.
BACKGROUND Local inflammatory changes, resembling those observed in atherosclerosis, have been recently
reported in degenerative aortic valvular stenosis. It is presently unknown whether systemic
signs of inflammation, similar to those observed in atherosclerosis, may be present in this
disorder.
METHODS C-reactive protein (CRP) was measured by enzyme immunoassay in 141 subjects: 62 with
trileaflet degenerative valvular aortic stenosis and 79 volunteers with similar demographic and
clinical characteristics. IgG antibodies against Helicobacter pylori (enzyme-linked immunosor-
bant assay) and Chlamydia pneumoniae (microimmunofluorescence assay) were also measured.
RESULTS C-reactive protein levels (mg/dl, mean 6 SD) were 0.848 6 1.42 in patients and 0.394 6
0.50 in controls (p 5 0.0001, Mann-Whitney U test). Seroprevalence of H. pylori was 68.7%
in patients and 79.7% in controls (p 5 NS), whereas seroprevalence of C. pneumoniae
infection was higher in patients than it was in controls (59.7% vs. 33%, p 5 0.003; chi-square
test). After adjustment for various covariates in multiple logistic regression, the odds ratio for
degenerative aortic stenosis was 3.41 for C. pneumoniae infection (95% confidence intervals
[CI]: 1.60 to 7.30) and 2.76 for CRP (95% CI: 1.08 to 7.05). There was no significant
difference in patients or controls in CRP levels according to the serostatus for C. pneumoniae.
CONCLUSIONS Systemic signs of inflammation, similar to those found in atherosclerosis, are present in
patients with degenerative aortic valve stenosis. They do not seem to be linked to C.
pneumoniae or H. pylori infection. (J Am Coll Cardiol 2001;38:1078–82) © 2001 by the
American College of Cardiology
It has recently been found that so-called chronic degener-
ative valvular aortic stenosis is an active process and that
histologic valve changes are predominantly inflammatory
and, in part, similar to those found in atherosclerotic
plaques (1). Furthermore, some classic risk factors for
atherosclerosis seem to predispose to valvular aortic stenosis
(2,3).
Since it is now firmly established that chronic systemic
inflammation may play an important role in the develop-
ment of atherosclerosis (4), it is possible that this condition
may also play a role in the development or progression of
degenerative valvular aortic stenosis. This hypothesis has
never been explored.
In this report, we compared the levels of C-reactive
protein (CRP), the most sensitive marker of systemic
inflammation, between patients with chronic degenerative
valvular disease and volunteers without this disease.
Furthermore, we evaluated whether Chlamydia pneu-
moniae and Helicobacter pylori, two microorganisms that are
able to induce chronic inflammatory changes (5–13) and
have been linked to coronary artery disease (5–7,14–21),
may be associated with alterations of CRP in patients with
degenerative valvular aortic stenosis.
METHODS
The study sample included consecutive patients with degen-
erative trileaflet valvular aortic stenosis and absence of
atherosclerotic lesions admitted to the Department of Car-
diac Surgery of the Catholic University of Rome for elective
valvular substitution from January 1998 to December 1999.
The absence of atherosclerosis was assessed by normal
angiography of coronary vessels, by less than 25% stenosis of
the carotid tree (Doppler ultrasonography) and by normal
physical examination of the lower limb arteries. A diagnosis
of degenerative valvular disease was made on the basis of
clinical criteria (no history of rheumatic disease) and the
echocardiographic finding of thickening and increased
echogenicity of the cusps (excluding the free edges) with
reduced systolic opening.
The degree of calcification of the aortic valve was assessed
on the basis of recently proposed echocardiographic criteria
From the *Medical Semiology and Methodology, Tor Vergata University, Rome,
Italy; †Clinica San Raffaele, Velletri, Italy; ‡Department of Cardiac Surgery,
§Institute of Microbiology, Catholic University of the “Sacred Heart,” Rome, Italy;
and \Department of Experimental Medicine and Biochemical Sciences, Tor Vergata
University, Rome, Italy. Supported, in part, by a grant of Ministero dell’Universita` e
Ricerca Scientifica-Programma di ricerca scientifica di interesse nazionale—anno
1999–2002.
Manuscript received January 30, 2001; revised manuscript received May 29, 2001,
accepted June 15, 2001.
Journal of the American College of Cardiology Vol. 38, No. 4, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01484-X
(22). The confirmation of calcification of the valvular
leaflets of the aortic valve at surgery was an additional
criterion. Aortic jet velocity (m/s) and aortic valve area
(cm2) were measured at echocardiography and taken as
parameters of aortic stenosis severity. Patients with echo-
cardiographic findings suggestive of congenital valve steno-
sis (identification of two cusps in systole and systolic cusp
doming, highly asymmetric thickening or both) or rheu-
matic valve stenosis (commissural fusion and mitral valve
involvement) were excluded.
At the time of hospitalization, key demographic and
clinical characteristics were collected including age, gender,
presence of traditional risk factors for atherosclerosis (hy-
pertension, diabetes, obesity, smoking, hyperlipidemia, pos-
itive family history). For the purposes of this study, patients
were defined as: hypertensive if they had a diastolic pressure
higher than 90 mm Hg and a systolic pressure higher than
140 mm Hg or if they were being treated for at least one
year for this disorder, diabetic if they had fasting levels of
glucose higher than 126 mg/dl in two distinct instances or
if they were being treated for at least one year with
hypoglycemic drugs, smokers if they reported a daily habit
of 10 cigarettes/day or more for at least one year during the
last 10 years, hyperlipidemic if they had a total cholesterol
level higher than 220 mg/dl or if they were being treated for
at least one year with lipid lowering drugs. Body mass index
(BMI) (kg/m2) was taken as a measure of obesity.
A control population of volunteers over 40 years of age,
relatives of patients hospitalized at the Department of
Internal Medicine of Tor Vergata University of Rome for
noncardiac, noninfectious diseases was enrolled during the
same time period as patient enrollment. The same clinical
and instrumental evaluations performed in patients were
made in controls, except for coronary angiography. A
negative clinical history for cardiac disease was a prerequisite
for inclusion in the study. Furthermore, all control subjects
performed a 12-lead electrocardiogram and echocardiogra-
phy; those with normal findings were admitted to the study.
Both patients and controls were living in the same geo-
graphic area (the Italian district of Lazio).
Informed consent was obtained by all patients and con-
trols for blood draws for the determination of CRP, and
IgG antibodies against H. pylori and C. pneumoniae. The
study protocol was approved by the ethical committee of our
institutions.
In the patient group, blood draws were performed during
the first 24 h of hospitalization, and all subjects were in
stable clinical condition. In the control group, blood was
taken within one week from the time that consent to
participate in the study was given.
To minimize external influence on CRP determination,
additional exclusion criteria, for patients and controls, were
a history of cancer or the development, during the month
preceding the inclusion in the study, of any active inflam-
matory or hematologic disorder.
All samples were kept at 280°C and were analyzed
simultaneously by technicians who were blinded to subject
group.
Determination of CRP. C-reactive protein was assessed
by rate nephelometry (Behring NA latex CRP; Behring
Institute, Scoppito, l’Aquila, Italy) and, in samples with less
than 0.25 mg of C-reactive protein per deciliter, enzyme
immunoassay (Imx, Abbott Laboratories, North Chicago,
Illinois), calibrated with the World Health Organization’s
International Reference Standard for CRP Immunoassay
(23); the range of value detected by the assay is 0.005 to
3 mg per deciliter (24).
Serology testing. The frozen sera of the patients and
controls were simultaneously investigated for IgG antibod-
ies to H. pylori by an enzyme linked immunosorbent assay
(Pyloryset, ORION Diagnostica, Espoo, Finland) by one of
the authors who was blinded to the disease status. Titers $
300 were regarded as positive. Detection of IgG antibodies
to C. pneumoniae was done by a microimmunofluorescence
assay obtained from Labsystem OY (Helsinki, Finland).
IgG titer $1:32 and ,1:512 were considered as evidence of
preexisting infection.
Statistical analysis. When not otherwise stated, data are
presented as mean 6 SD. A two-tailed value of p # 0.05
was considered statistically significant.
To evaluate whether the two groups were comparable for
the recorded clinical parameters (age, gender, smoking
habit, diabetes, hypertension, family history of coronary
artery disease, hyperlipidemia and BMI), a univariate anal-
ysis was performed. Student t test was used to compare
continuous variables, and chi-square was used to compare
categorical variables.
Since CRP is not normally distributed, a nonparametric
test (Mann-Whitney U test) was used when comparing this
variable between patients and controls.
To evaluate whether CRP levels may be related to the
severity of the aortic valve stenosis, a tertile analysis of CRP
levels in relation to the aortic jet velocity and aortic valve
surface area was performed by means of one way analysis of
variance.
The seroprevalence of C. pneumoniae and H. pylori was
compared between patients and controls using the chi-
square test. Unconditional logistic regression was used to
assess the independent association of CRP or of a positive
antibody titer with degenerative valvular aortic stenosis,
while simultaneously controlling for age (years), gender,
BMI (kg/m2) ($28 vs. ,28), smoking (smokers vs. non-
smokers), history of hypertension, hyperlipidemia, dia-
betes and familial history of coronary artery disease. Finally,
Abbreviations and Acronyms
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CRP values were compared between infected and nonin-
fected subjects in cases and controls separately with the
Mann-Whitney U test. All computations were made with
MINITAB software release 13 (MINITAB INC, State
College, Pennsylvania).
RESULTS
Sixty-eight patients (group 1) and 92 healthy controls
(group 2) were considered during the study period. Six
subjects of group 1 and 13 subjects of group 2 were excluded
from the analysis of the data for the following reasons:
history of rheumatic fever elicited after blood drawing (six
subjects, group 1), abnormal electrocardiogram (eight pa-
tients, group 2) and abnormal echocardiographic findings
(five subjects, group 2). Data, therefore, refer to 62 patients
of group 1 and 79 patients of group 2.
The primary indication for valve replacement was heart
failure in 38 (61%), syncope or near syncope in 18 (29%),
angina in 4 (6%) and severe asymptomatic aortic stenosis in
2 (4%).
Factors considered for univariate analysis are shown in
Table 1. None of the considered factors showed significant
differences between the two groups. C-reactive protein
levels (mg/dl) were 0.848 6 1.42 in group 1 vs. 0.394 6
0.50 in group 2 (p 5 0.0001). Table 2 shows the prevalence
of infection with C. pneumoniae and H. pylori in the two
groups. Seroprevalence of infection with C. pneumoniae was
59.7% in patients and 33% in controls (p 5 0.003), whereas
the prevalence of H. pylori was not significantly different
between the two groups, being 68.7% and 79.7%, respectively.
Aortic jet velocity values (m/s) of patients belonging to
different tertiles of CRP levels were as follows: lower tertile:
4.86 6 0.79; intermediate tertile: 5.18 6 0.47; higher
tertile: 5.03 6 0.61 (p 5 NS); the corresponding values of
aortic-valve surface area (cm2) were: 0.62 6 0.14, 0.58 6
0.12 and 0.59 6 0.14, respectively (p 5 NS). Aortic valve
surface area was not available in seven patients.
The CRP level (mg/dl) was 1.0 6 1.7 in patients with
moderate valve calcification and 0.71 6 1.04 in those with
severe calcification (p 5 NS).
Tables 3 and 4 present the results of multivariable logistic
regression analyses in which the association between C.
pneumoniae and CRP and aortic degenerative valvular ste-
nosis was adjusted for age and gender and a variety of
potential confounders. The odds ratio (OR) for the disease
given a seropositivity for C. pneumoniae was 3.45 (95%
confidence interval [CI]: 1.67 to 7.12) in the first model and
3.41 (95% CI: 1.60 to 7.30) in the fully adjusted model; the
ORs for the disease according to CRP levels were 2.62 (95%
CI: 1.06 to 6.49) and 2.76 (95% CI: 1.08 to 7.05),
respectively. Table 5 shows measures of central tendency for
CRP in patients and controls according to C. pneumoniae
IgG serostatus. None of the comparisons was significantly
different between the two groups.
DISCUSSION
Main findings. Our data indicate that a systemic inflam-
matory response, evaluated by CRP, is present in patients
with severe degenerative trileaflet aortic stenosis requiring
surgical repair. We also evaluated whether H. pylori and C.
pneumoniae may be associated with the inflammatory re-
sponse since these two agents have been extensively studied
in this regard in patients with atherosclerosis (2–18). In this
study, we did not detect any difference in the prevalence of
H. pylori infection between patients and controls, whereas
the prevalence of IgG antibodies against C. pneumoniae was
increased in patients with degenerative valvular aortic ste-
nosis. However, no difference in CRP levels was found
between patients with and without C. pneumoniae infection.
Pathophysiologic and clinical implications. The presence
of chronic systemic inflammation in patients with degener-
ative aortic valvular stenosis adds support to the hypothesis
that a common pathophysiologic pathway is present in this
condition and in atherosclerosis.
A similarity between the inflammatory infiltrate at the
level of the aortic plaque and that found at the level of the




(n 5 79) Odds Ratio
Age (yr) 61.09 6 11.7 62.8 6 9.3 0.99 (0.96–1.03)†
Men 53.1% 50.6% 1.11 (0.57–2.16)
Smokers 25.0% 17.7% 1.48 (0.65–3.36)
Hypertension 25.0% 12.6% 1.98 (0.92–5.55)
Hyperlipidemia 6.3% 5.0% 1.29 (0.31–5.39)
Diabetes 6.3% 3.8% 1.75 (0.38–8.11)
BMI . 28 28.1% 25.3% 1.06 (0.51–2.21)
Family history of
CHD
6.3% 5.0% 1.29 (0.31–5.39)
†Values in parentheses are 95% confidence intervals.
BMI 5 body mass index; CHD 5 coronary heart disease.
Table 2. Seroprevalence of Chlamydia pneumoniae and




(n 5 79) p Value
H. pylori positive 68.7% 79.7% NS
C. pneumoniae positive 59.4% 33.0% 0.003
Table 3. Odds Ratios for Chlamydia pneumoniae in
Aortic Valvular Stenosis After Adjustment for Possible
Confounding Factors
Odds Ratio Odds Ratio
C. pneumoniae infection 3.45 (1.67–7.12)* 3.41 (1.60–7.30)
Age (yr) 0.99 (0.95–1.03) 0.99 (0.95–1.03)
Gender 0.99 (0.50–1.99) 0.81 (0.38–1.75)




BMI . 28 1.05 (0.47–2.36)
Family history of CHD 2.20 (0.43–11.29)
*Values in parentheses are 95% confidence intervals.
BMI 5 body mass index; CHD 5 coronary heart disease.
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diseased valve has been shown in recent years (1). Our
findings show that an association with a systemic inflam-
matory status is shared by these two disorders.
This fact suggests that, on the basis of the host suscep-
tibility, the presence of the same risk factor (chronic
inflammation) may induce a different disease. Alternatively,
it is possible that different disorders may be associated at a
certain point of their natural history with a systemic
inflammatory reaction.
Elevated CRP levels, whether preceding the development
of degenerative valvular aortic stenosis or established at
some time during the course of the disease, may have a
detrimental influence on the natural history of the disease by
inducing local activation of complement and subsequent
amplification of local inflammation and cellular damage
(25).
From a clinical point of view, it is important to note that
the deleterious effects of long-term CRP activation may
theoretically be halted by aspecific long-term anti-
inflammatory therapy (26) or by a specific treatment against
the factor(s) responsible for its increase. Although the two
putative factors considered in the present study (H. pylori
and C. pneumoniae) did not show an association with
increased CRP levels, our findings, showing an increased
seroprevalence of C. pneumoniae in patients with degenera-
tive valvular aortic stenosis, are in accordance with recent
data showing a high frequency of this agent in aortic valves
(27–29). Our data, therefore, support the performance of
trials of antibiotic therapy against C. pneumoniae in order to
evaluate whether the elimination of this organism may
modify the natural history of the disease.
Our findings in the context of available literature. No
data are available in the literature on the possible correlation
between CRP levels and valvular degenerative aortic steno-
sis or on the relationship between seroprevalence of H. pylori
infection and this disorder.
Three studies (27,28,30) evaluated evidence of previous
infection with C. pneumoniae by means of serum IgG
antibodies, and seroprevalence ranged from 65% to 86%.
Although the populations considered in these studies were
heterogeneous in comparison with our patients (patients
with rheumatic disease, bicuspid valves and concomitant
atherosclerosis were included), from one of these reports
(27) it was possible to extrapolate data for patients with
characteristics similar to ours; the prevalence of seropositiv-
ity to C. pneumoniae was 71% in this subgroup, which is
slightly higher than the 59% found in this study, giving
support to the hypothesis that there is a link between this
organism and degenerative aortic valvular stenosis.
However, our data seem to exclude that the association
between C. pneumoniae and degenerative valvular aortic
stenosis may be mediated by chronic systemic inflammation
induced by the organism, since there was no difference in
the levels of CRP between infected and noninfected pa-
tients. Thus, the possible causal role, if any, of C. pneu-
moniae in the pathogenesis and evolution of degenerative
aortic valvular stenosis is probably confined to a local action
at the level of valvular tissue.
The mechanism(s) responsible for the observed increase
of CRP in patients with degenerative aortic valvular stenosis
remain to be elucidated.
Study limitations. The cross-sectional nature of the study
does not allow us to recognize whether the detected increase
in CRP levels in degenerative valvular aortic stenosis plays a
causal role in the development of the disease or is induced
by the disease itself or by associated conditions. Further-
more, our analysis was restricted to patients with an ad-
vanced stage of the disease, requiring surgical therapy. We
feel that this fact may at least, in part, explain why we were
not able to detect a relationship between CRP levels and the
severity of aortic stenosis. For example, previous studies
have reported that patients with moderate-to-severe aortic
calcification or those with high jet velocity had a poorer
prognosis than patients without these characteristics
(22,31). Both these studies, however, enrolled only asymp-
tomatic patients, and aortic valve replacement represented
the end point for an adverse outcome. In this study, all
patients required surgical therapy, had moderate-to-severe
aortic calcification and had a high jet velocity. Thus, the lack
of patients with mild disease in our series probably did not
allow us to evaluate the possible relationship between
systemic inflammation and the severity of aortic valve
stenosis.
Should the presence of chronic systemic inflammation be
Table 4. Odds Ratios for CRP in Aortic Valvular Stenosis After
Adjustment for Possible Confounding Factors
Odds Ratio Odds Ratio
CRP 2.62 (1.06–6.49)* 2.76 (1.08–7.05)
Age (yr) 0.99 (0.96–1.03) 0.99 (0.95–1.03)
Gender 1.21 (0.61–2.41) 0.97 (0.45–2.08)




BMI . 28 1.14 (0.51–2.54)
Family history of CHD 1.55 (0.31–7.72)
*Values in parentheses are 95% confidence intervals.
BMI 5 body mass index; CHD 5 coronary heart disease; CRP 5 C-reactive
protein.
Table 5. CRP in Patients and Controls According to Chlamydia
pneumoniae Infection
C. P. 1 C. P. 2 Odds Ratio
Patients (n 5 62) n 5 37 n 5 25
CRP
Median 0.5 0.5 0.83 (0.30–2.30)*
Controls (n 5 79) n 5 26 n 5 53
CRP
Median 0.2 0.2 0.38 (0.14–1.02)
*Values in parentheses are 95% confidence intervals. For calculating odds ratio and
confidence intervals, the population was dichotomized into those with high and those
with low concentration of CRP, based on the median values.
C. P. 1 5 C. pneumoniae positive patients; C. P. 2 5 C. pneumoniae negative
patients; CRP 5 C-reactive protein.
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limited to the final stages of the disease, the potential
usefulness of anti-inflammatory treatment would be greatly
reduced.
Finally, although quite relevant from a statistical point of
view, some overlapping of CRP levels was observed between
patients and controls. This finding seems to suggest that
chronic systemic inflammation cannot be regarded as a
universal phenomenon in degenerative valvular aortic ste-
nosis.
Conclusions. To our knowledge, this study shows for the
first time that signs of chronic systemic inflammation,
assessed by means of CRP, are present in patients with
degenerative aortic valvular stenosis. This fact may influence
the natural history of the disease and may have therapeutic
implications. C. pneumoniae, although linked to this disor-
der, is probably not responsible for this finding.
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